Annual report
7446.TEDINET S100XAMG
Period2024-10-01 → 2025-09-30
Filed2025-12-17
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥34.4bn | 2024-10-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥32.2bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥35.1bn | 2022-10-01 → 2023-09-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥37.3bn | 2021-10-01 → 2022-09-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥36.2bn | 2020-10-01 → 2021-09-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥518m | 2024-10-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥353m | 2023-10-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥595m | 2024-10-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥408m | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥808m | 2022-10-01 → 2023-09-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-10-01 → 2022-09-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥759m | 2020-10-01 → 2021-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥639m | 2024-10-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥380m | 2023-10-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥429m | 2024-10-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥237m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥556m | 2022-10-01 → 2023-09-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥658m | 2021-10-01 → 2022-09-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥517m | 2020-10-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥432m | 2024-10-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥240m | 2023-10-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥18.4bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥17.2bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥18.9bn | at 2023-09-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥17.5bn | at 2022-09-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥16.1bn | at 2021-09-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.4bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥9.7bn | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥8.0bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2023-09-30v | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-09-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.3bn | at 2021-09-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥925m | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥764m | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥911m | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2023-09-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-09-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥660m | at 2021-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥150m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.0bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥886m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥322m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥19m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥108m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥335m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥92m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥172m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3m | 2024-10-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥210m | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥96m | 2022-10-01 → 2023-09-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥186m | 2021-10-01 → 2022-09-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥221m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥475.93 | 2024-10-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥263.54 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥617.29 | 2022-10-01 → 2023-09-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥728.76 | 2021-10-01 → 2022-09-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥564.91 | 2020-10-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥8,798.59 | at 2025-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥8,233.87 | at 2024-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥7,971.19 | at 2023-09-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥7,330.63 | at 2022-09-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥6,829.86 | at 2021-09-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 43.0% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.7% | at 2022-09-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2021-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.6% | 2024-10-01 → 2025-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2023-10-01 → 2024-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2022-10-01 → 2023-09-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-10-01 → 2022-09-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2020-10-01 → 2021-09-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 315 | at 2025-09-30 | Cons. | Number of employees |
| Employees | 330 | at 2024-09-30 | Cons. | Number of employees |
| Employees | 321 | at 2023-09-30v | Cons. | Number of employees |
| Employees | 321 | at 2022-09-30v | Cons. | Number of employees |
| Employees | 316 | at 2021-09-30d | Cons. | Number of employees |
| Revenue | ¥27.0bn | 2024-10-01 → 2025-09-30 | Standalone | Net sales |
| Revenue | ¥24.7bn | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥27.4bn | 2022-10-01 → 2023-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥28.4bn | 2021-10-01 → 2022-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥27.8bn | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥496m | 2024-10-01 → 2025-09-30 | Standalone | Operating income |
| Operating income | ¥345m | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Ordinary income | ¥570m | 2024-10-01 → 2025-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥393m | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥739m | 2022-10-01 → 2023-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥846m | 2021-10-01 → 2022-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥633m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥615m | 2024-10-01 → 2025-09-30 | Standalone | Income before income taxes |
| Profit before tax | ¥368m | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Net income | ¥411m | 2024-10-01 → 2025-09-30 | Standalone | Profit loss |
| Net income | ¥230m | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | ¥495m | 2022-10-01 → 2023-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥547m | 2021-10-01 → 2022-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥424m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥14.9bn | at 2025-09-30 | Standalone | Assets |
| Total assets | ¥13.6bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥15.2bn | at 2023-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.1bn | at 2022-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥13.0bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥7.4bn | at 2025-09-30 | Standalone | Liabilities |
| Total liabilities | ¥6.6bn | at 2024-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥7.5bn | at 2025-09-30 | Standalone | Net assets |
| Net assets / equity | ¥7.0bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥6.8bn | at 2023-09-30v | Standalone | Net assets |
| Net assets / equity | ¥6.3bn | at 2022-09-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.0bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥819m | at 2025-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥663m | at 2024-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥456.63 | 2024-10-01 → 2025-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥255.69 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥549.54 | 2022-10-01 → 2023-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥606.07 | 2021-10-01 → 2022-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥463.89 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥125 | 2024-10-01 → 2025-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥105 | 2023-10-01 → 2024-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥105 | 2022-10-01 → 2023-09-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥115 | 2021-10-01 → 2022-09-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥105 | 2020-10-01 → 2021-09-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥8,276.71 | at 2025-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥7,802.34 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥7,552.81 | at 2023-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥6,987.67 | at 2022-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥6,615.32 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 50.1% | at 2025-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2023-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.7% | at 2022-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.4% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.7% | 2024-10-01 → 2025-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2023-10-01 → 2024-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2022-10-01 → 2023-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-10-01 → 2022-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 960,000 | at 2025-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2023-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2022-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 960,000 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 245 | at 2025-09-30 | Standalone | Number of employees |
| Employees | 254 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 244 | at 2023-09-30v | Standalone | Number of employees |
| Employees | 236 | at 2022-09-30v | Standalone | Number of employees |
| Employees | 230 | at 2021-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| Academia Life Science Sales Groupreportable segment | employees | at 2025-09-30 | 25 pure |
| Academia Life Science Sales Groupreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥2.4bn |
| Academia Life Science Sales Groupreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥2.4bn |
| Industry Sales Groupreportable segment | employees | at 2025-09-30 | 54 pure |
| Industry Sales Groupreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥17.9bn |
| Industry Sales Groupreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥17.9bn |
| Medical Sales Groupreportable segment | employees | at 2025-09-30 | 73 pure |
| Medical Sales Groupreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥14.1bn |
| Medical Sales Groupreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-10-01 → 2025-09-30 | ¥34.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-10-01 → 2025-09-30 | ¥34.4bn |
| Academia Life Science Sales Groupreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| Academia Life Science Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥1.9bn |
| Industry Sales Groupreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥16.1bn |
| Industry Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥16.1bn |
| Medical Sales Groupreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥14.1bn |
| Medical Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-10-01 → 2024-09-30 | ¥32.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-10-01 → 2024-09-30 | ¥32.2bn |
| Academia Life Science Sales Groupreportable segment | employees | at 2025-09-30 | 25 pure |
| Industry Sales Groupreportable segment | employees | at 2025-09-30 | 49 pure |
| Medical Sales Groupreportable segment | employees | at 2025-09-30 | 28 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,679
| Item | Context | Value | Unit |
|---|---|---|---|
| Metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)化学製品の取り扱いに関する資格の新規取得者数（新規学卒入社） | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)2025年９月期 | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)名 | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | Original text (Japanese)化学製品の取り扱いに関する資格の新規取得者数（既存従業員） | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | Original text (Japanese)名 | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | Original text (Japanese)全社員のうち化学製品の取り扱いに関する有資格者数 | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | Original text (Japanese)名 | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | Original text (Japanese)女性課長級以上の人数 | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | Original text (Japanese)2030年まで | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | Original text (Japanese)名 | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | Original text (Japanese)女性主任級以上の人数 | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | Original text (Japanese)名 | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所スタンダード市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Shareholding by shareholder category (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)㈱青森みちのく銀行 | |
| Address major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)青森県青森市橋本1-9-30 | |
| Name major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)東北化学薬品取引先持株会 | |
| Address major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)青森県弘前市大字神田1-3-1 | |
| Name major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)東北化学薬品従業員持株会 | |
| Address major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)青森県弘前市大字神田1-3-1 | |
| Name major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Original text (Japanese)東京中小企業投資育成㈱ | |
| Address major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Original text (Japanese)東京都渋谷区渋谷3-29-22 | |
| Name major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)東 康夫 | |
| Address major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)青森県弘前市 | |
| Name major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)東 康之 | |
| Address major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)青森県弘前市 | |
| Name major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)東ソー・ニッケミ㈱ | |
| Address major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)東京都中央区京橋2-1-3 | |
| Name major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)日本曹達㈱ | |
| Address major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内2-7-2 | |
| Name major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)シスメックス㈱ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |